Redox Imbalance in Crohn's Disease Patients Is Modulated by Azathioprine Publisher Pubmed



Tavassolifar MJ¹ ; Changaei M¹ ; Salehi Z¹ ; Ghasemi F² ; Javidan M¹ ; Nicknam MH¹ ; Pourmand MR² Show Affiliations
Source: Redox Report Published:2021

Abstract

Background: Crohn's disease (CD) is a chronic inflammatory disease without a specific cause. Inflammation in these patients can disturb the oxidants/antioxidants balance and results in oxidative stress that plays a destructive role. This study aimed to evaluate the gene expression of sod1, sod2, cat, nrf2 and gp91phox in CD patients before and after Azathioprine (Aza) consumption. Method: Peripheral bloodmononuclear cells (PBMCs) were separated from CD patients (n= 15, mean age = 33.6 ± 1.8) before and after treatment with Aza and healthy controls (n= 15, mean age = 31.5 ± 1.2). The expression levels of sod1, sod2, cat, nrf2 and gp91phox were measured in byusing real-time qRT-PCR technique. Result: The expression levels of gp91phox (P-value < 0.001), cat (P-value < 0.05), sod1 (P-value < 0.001), nrf2 (P-value < 0.001) were significantly increased compared to control group. Following treatment with Aza, the decreased expression levels of gp91phox (P-value < 0.05), cat (P-value < 0.05), sod1(P-value < 0.001) and nrf2 (P-value < 0.001) were observed in CD patients. Conclusion: Overall, our results showed that prescription of Azathioprine can lead to the altered expression of redox system-related genes in patients with CD. © 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.